Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.
In Japan, the use of amantadine for treatment of influenza A virus infection was not accepted until November 1998, although it was widely used for treatment of Parkinsonism. Since then, we have monitored the emergence of amantadine-resistant viruses and isolated two viruses from patients on long-term treatment with amantadine.
Iwahashi
J
J
Department of Virology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Tsuji
K
K
Ishibashi
T
T
Kajiwara
J
J
Imamura
Y
Y
Mori
R
R
Hara
K
K
Kashiwagi
T
T
Ohtsu
Y
Y
Hamada
N
N
Maeda
H
H
Toyoda
M
M
Toyoda
T
T
D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000494:pharmacology* / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000150:complications; D004352:Drug Resistance, Microbial; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype; D009980:Influenza A virus / Q000187:drug effects* / Q000302:isolation & purification; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D007564:Japan; D008969:Molecular Sequence Data; D010300:Parkinson Disease / Q000188:drug therapy; D013577:Syndrome
D000978:Antiparkinson Agents; D000998:Antiviral Agents; D000547:Amantadine